The latest leukaemia news
A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus…
Patients with acute myeloid leukaemia who have lower education levels and lower income are less…
In early results from a non-randomised study, the biologic agent epcoritamab, which leverages patients’ immune…
Many patients with acute myeloid leukemia (AML) can be cured by a transplant of blood-forming…
First responders who worked at Ground Zero in the aftermath of the 2001 attacks on…
The National Institutes of Health (NIH) USA, has launched a proof-of-concept precision medicine clinical trial…
On October 29, 2024, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix,…
A landmark study led by WEHI and La Trobe University has found a potential new…
Over four hundred people, 80% of them being children under 14 years old, will be…
A new editorial was published in Oncotarget’s Volume 15 on October 1, 2024, entitled, “Transplant or no transplant…